Prokidney (PROK) Assets Average (2021 - 2026)
Prokidney's (PROK) quarterly Assets Average came in at $314.2 million in Q1 2026, down 25.83% year-on-year from $423.6 million in Q1 2025, and down 8.56% on a QoQ basis from $343.6 million in Q4 2025.
Prokidney (PROK) Assets Average (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Assets Average data on file, last reported at $314.2 million in Q1 2026.
- On a quarterly basis, Assets Average fell 25.83% year-over-year to $314.2 million in Q1 2026; TTM through Mar 2026 was $314.2 million, a 25.83% decrease from a year earlier, with the FY2025 full-year figure at $388.3 million, down 9.86% from the prior year.
- Assets Average for Q1 2026 stood at $314.2 million, down from $343.6 million in the prior quarter.
- Over the last five years, Assets Average for PROK reached as high as $525.2 million in Q4 2022 and fell as low as $145.5 million in Q1 2022.
- Historically, Assets Average has averaged $402.3 million across 5 years, with a median of $423.6 million in 2025.
- Across the five-year window, Assets Average surged 260.06% in 2022 and retreated 25.83% in 2026, its largest moves.
- Year by year, Assets Average stood at $525.2 million in 2022, then fell by 16.95% to $436.2 million in 2023, then climbed by 4.99% to $457.9 million in 2024, then dropped by 24.97% to $343.6 million in 2025, then dropped by 8.56% to $314.2 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $314.2 million in Q1 2026, $343.6 million in Q4 2025, and $361.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Prokidney | 96.31 Mn | 96.31 Mn | - | 314.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 314.18 Mn |
| Dec 31, 2025 | 343.59 Mn |
| Sep 30, 2025 | 361.87 Mn |
| Jun 30, 2025 | 389.10 Mn |
| Mar 31, 2025 | 423.57 Mn |
| Dec 31, 2024 | 457.93 Mn |
| Sep 30, 2024 | 486.98 Mn |
| Jun 30, 2024 | 443.46 Mn |
| Mar 31, 2024 | 404.16 Mn |
| Dec 31, 2023 | 436.18 Mn |
| Sep 30, 2023 | 468.01 Mn |
| Jun 30, 2023 | 489.69 Mn |
| Mar 31, 2023 | 506.57 Mn |
| Dec 31, 2022 | 525.22 Mn |
| Sep 30, 2022 | 391.72 Mn |
| Jun 30, 2022 | 250.88 Mn |
| Mar 31, 2022 | 145.53 Mn |
| Dec 31, 2021 | 145.87 Mn |
| Sep 30, 2021 | 126.03 Mn |